drug
nirmatrelvir + ritonavir
pre_registrationupdated 6mo agoby $PFE PFIZER INC
community read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying nirmatrelvir + ritonavir
News(10)
- Moderna enjoys stable vaccine sales thanks to global COVID uptakeWhile Moderna preps an entry to the oncology market next year with a personalized cancer vaccine, COVID sales are holding steady with several other vaccine launches underway around the world.biospace · 12d ago
- Pfizer, fresh to China’s obesity market, looks to Viagra model to competePfizer is calling upon lessons learned from one of the first drugs ever made available on the internet—Viagra—as it commercializes a new obesity drug in China.biospace · 15d ago
- Pfizer flat in Q3 despite 32% growth for new and acquired productsSales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.biospace · 16d ago
- Telemedicine company offers GLP-1s for addictionA CDC Covid restructuring, public trust in Fauci, and more health news from Morning Roundsstat · 2mo ago
- An administrative gap delays access to new pancreatic cancer treatmentA new wave of illegal fruity vapes, more and more kids on GLP-1s, and other health news from Morning Roundsstat · 2mo ago
- Disabled workers at greater risk of losing health insuranceAn organ transplant first, new details on ADA conference controversy, and more health news from Morning Roundsstat · 2mo ago
- HHS flip-flops on disability lawsuitDrug overdose deaths decreasing, a path to patients for AI devices, and more health news from Morning Roundsstat · 2mo ago
- HHS spins a tale of a would-be content creator childThe next DSM and the algorithm, an unexpected discovery on alpha-gal syndrome, and more health news from Morning Roundsstat · 2mo ago
- Paxlovid did not help long Covid, study findsNew Trump drug pricing deals, weed edibles and driving research, and more health news from Morning Roundsstat · 2mo ago
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 3mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that